J&J Pharmaceuticals Surge as Medical Device Unit Falters

A 2.7% drop in share price followed Johnson & Johnson's second-quarter results, revealing a sharp divide between the company’s high-performing drug portfolio and its struggling medical device division. While pharmaceutical revenues reached new heights, the recent $16.6 billion acquisition of Abiomed faced unexpected headwinds in the U.S. market.

Editorial·July 15, 2026·reads: 901

The primary drag on the medical technology unit stemmed from declining demand for Impella heart pumps. CFO Joseph Wolk attributed the cooling interest to a recent UK study, marking a significant reversal after the product line posted 14% growth during the first quarter. Despite this, management maintains that upcoming clinical data will validate the pump's utility in complex, high-risk coronary procedures.

Conversely, the pharmaceutical segment provided a strong buffer against these device-related setbacks. Sales of the psoriasis treatment Tremfya jumped 72.5%, effectively offsetting the market share erosion of the legacy drug Stelara. Bolstered by the consistent performance of products like Darzalex, the company raised its annual sales guidance to approximately $101.1 billion.